Economic Reporter :
Beximco Pharmaceuticals has started the export of its third item -Methocarbamol (500mg and 700mg) to the United States.
Following the successful marketing of Carvedilol and Sotalol in August 2016 and November 2017, respectively in the world’s largest pharmaceuticals market, the first consignment of its third item was delivered on this April 21, said a press release on Tuesday.
Methocarbamol is generic equivalent to muscle relaxant drug Robaxin from Auxilium Pharmaceuticals. According to IQVIA market data, the US market for Methocarbamol is currently valued at USD 23.37 million.
Beximco Pharma managing director Nazmul Hassan, MP, said: “We will continue to focus on growing our portfolio in the US, which we believe will be a major export market for Beximco Pharma in the coming years.”
“We remain focused on our strategic goal to bring high quality, differentiated products to both developed and key emerging markets to create value for our customers and shareholders,” he added.
Beximco Pharma is the only Bangladeshi pharmaceutical company to export medicine to the US market following its manufacturing site approval by the US Food and Drug Administration in June 2015.
Beximco Pharma currently has a global footprint in more than 50 countries and has been accredited by the leading global regulatory authorities namely US FDA, AGES (EU), TGA (Australia), Health Canada, GCC (Gulf) and TFDA (Taiwan).
Beximco Pharmaceuticals has started the export of its third item -Methocarbamol (500mg and 700mg) to the United States.
Following the successful marketing of Carvedilol and Sotalol in August 2016 and November 2017, respectively in the world’s largest pharmaceuticals market, the first consignment of its third item was delivered on this April 21, said a press release on Tuesday.
Methocarbamol is generic equivalent to muscle relaxant drug Robaxin from Auxilium Pharmaceuticals. According to IQVIA market data, the US market for Methocarbamol is currently valued at USD 23.37 million.
Beximco Pharma managing director Nazmul Hassan, MP, said: “We will continue to focus on growing our portfolio in the US, which we believe will be a major export market for Beximco Pharma in the coming years.”
“We remain focused on our strategic goal to bring high quality, differentiated products to both developed and key emerging markets to create value for our customers and shareholders,” he added.
Beximco Pharma is the only Bangladeshi pharmaceutical company to export medicine to the US market following its manufacturing site approval by the US Food and Drug Administration in June 2015.
Beximco Pharma currently has a global footprint in more than 50 countries and has been accredited by the leading global regulatory authorities namely US FDA, AGES (EU), TGA (Australia), Health Canada, GCC (Gulf) and TFDA (Taiwan).
